Health News

The U.S. Food and Drug Administration approved a new genetic test that will help health care professionals determine if women with breast cancer are HER2-positive and, therefore, candidates for Herceptin (trastuzumab), a commonly used breast cancer treatment. The test, called Inform Dual ISH, allows for measurement of the number of copies of the HER2 gene in tumor tissue…

Read more

Filed under: Pharmacy News
Tags: Breast Cancer, cancer, Drug, gene, Genetic, Pharmacy, Tumor

Related posts

• Study finds Olaparib can reduce tumor size in ovarian cancer women (0)
  Understanding the underlying genetic weakness of certain types of cancer may lead to targeted therapy and provide the key to effective treatment, a new study suggests. An international consortium of researchers has shown that an investigational drug, Olaparib, can reduce the size of tumors in women with advanced hereditary ovarian cancer with BRCA gene mutations. Read [...]
  
  
• Major study shoots for personalized breast cancer drugs (0)
  Mutations in BCRA1 and BCRA2 genes are mainly associated with increased risk of breast cancer in women. Recently many other genetic variants have been found to be associated with breast cancer. Read more [tags] Pharmacy News [/tags]
  
  
• FDA Approves New Test To Help Determine If Breast Cancer Patients Are Candidates For Herceptin Treatment (0)
  The U.S. Food and Drug Administration today approved a new genetic test that will help health care professionals determine if women with breast cancer are HER2-positive and, therefore, candidates for Herceptin (trastuzumab), a commonly used breast cancer treatment. The test, called Inform Dual ISH, allows for measurement of the number of copies of the HER2 [...]
  
  
• Treatment with estrogen-lowering drugs shrinks tumors and reduces mastectomy rates in breast cancer patients (0)
  In the first large trial of its kind in the United States, researchers have shown that estrogen-lowering drugs can shrink tumors and reduce mastectomy rates for patients with stage 2 or 3 breast cancer. Read more [tags] Pharmacy News [/tags]
  
  
• Targeting mutant BRAF can kill cancer cells, but cannot finish off melanoma (0)
  This past summer saw a revolution in melanoma therapy. Patients whose melanoma lesions contain a mutation in the BRAF gene were successfully treated with a BRAF-specific inhibitor, PLX4032. Reports of the drug trial described shrinking tumors and improved health. Yet seven months after therapy began the tumors returned and resumed growing. Now, scientists at The [...]